1
|
van der Wal DE, Davis AM, Mach M, Marks DC. The role of neuraminidase 1 and 2 in glycoprotein Ibα-mediated integrin αIIbβ3 activation. Haematologica 2019; 105:1081-1094. [PMID: 31273092 PMCID: PMC7109719 DOI: 10.3324/haematol.2019.215830] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2019] [Accepted: 07/03/2019] [Indexed: 12/18/2022] Open
Abstract
Upon vascular injury, platelets adhere to von Willebrand Factor (VWF) via glycoprotein Ibα (GPIbα). GPIbα contains many glycans, capped by sialic acid. Sialic acid cleavage (desialylation) triggers clearance of platelets. Neuraminidases (NEU) are responsible for desialylation and so far, NEU1-4 have been identified. However, the role of NEU in healthy platelets is currently unknown. Aim of the study was to study the role of NEU1 and NEU2 in platelet signalling. Membrane association of platelet attached glycans, NEU1 and NEU2 was measured following activation with agonists using flow cytometry. Adhesion on fibrinogen, aggregation and fibrinogen-binding were assessed with/without the NEU-inhibitor, 2-deoxy-2-3-dide-hydro-N-acetylneuraminic acid. Cellular localisation of NEU1 and NEU2 was examined by fluorescence microscopy. Desialylation occurred following GPIbα-clustering by VWF. Basal levels of membrane NEU1 were low; glycoprotein Ibα-clustering induced a four-fold increase (n=3, P<0.05). Inhibition of αIIbβ3-integrin prevented the increase in NEU1 membrane-association by ~60%. Membrane associated NEU2 increased two-fold (n=3, P<0.05) upon VWF-binding, while inhibition/removal of GPIbα reduced the majority of membrane associated NEU1 and NEU2 (n=3, P<0.05). High shear and addition of fibrinogen increased membrane NEU1 and NEU2. NEU-inhibitior prevented VWF-induced αIIbβ3-integrin activation by 50% (n=3, P<0.05), however, promoted VWF-mediated agglutination, indicating a negative feedback mechanism for NEU activity. NEU1 or NEU2 were partially co-localised with mitochondria and α-granules respectively. Neither NEU1 nor NEU2 co-localised with lysosomal-associated membrane protein 1. These findings demonstrate a previously unrecognised role for NEU1 and NEU2 in GPIbα–mediated and αIIbβ3-integrin signalling.
Collapse
Affiliation(s)
| | - April M Davis
- Australian Red Cross Lifeblood (formerly known as Blood Service)
| | - Melanie Mach
- Australian Red Cross Lifeblood (formerly known as Blood Service)
| | - Denese C Marks
- Australian Red Cross Lifeblood (formerly known as Blood Service).,Sydney Medical School, Uinversity of Sydney, Sydney, NSW, Australia
| |
Collapse
|
2
|
Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M, Zhu L, Zeng Q, Tao L, Zhai ZM, Peng J, Hou M, Leytin V, Freedman J, Hoffmeister KM, Ni H. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015; 6:7737. [PMID: 26185093 PMCID: PMC4518313 DOI: 10.1038/ncomms8737] [Citation(s) in RCA: 237] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 06/05/2015] [Indexed: 12/21/2022] Open
Abstract
Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by autoantibodies against platelet GPIIbIIIa and/or the GPIb complex. Current theory suggests that antibody-mediated platelet destruction occurs in the spleen, via macrophages through Fc-FcγR interactions. However, we and others have demonstrated that anti-GPIbα (but not GPIIbIIIa)-mediated ITP is often refractory to therapies targeting FcγR pathways. Here, we generate mouse anti-mouse monoclonal antibodies (mAbs) that recognize GPIbα and GPIIbIIIa of different species. Utilizing these unique mAbs and human ITP plasma, we find that anti-GPIbα, but not anti-GPIIbIIIa antibodies, induces Fc-independent platelet activation, sialidase neuraminidase-1 translocation and desialylation. This leads to platelet clearance in the liver via hepatocyte Ashwell-Morell receptors, which is fundamentally different from the classical Fc-FcγR-dependent macrophage phagocytosis. Importantly, sialidase inhibitors ameliorate anti-GPIbα-mediated thrombocytopenia in mice. These findings shed light on Fc-independent cytopenias, designating desialylation as a potential diagnostic biomarker and therapeutic target in the treatment of refractory ITP.
Collapse
Affiliation(s)
- June Li
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - Dianne E van der Wal
- 1] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [2] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8 [3] Canadian Blood Services, Ottawa, Ontario, Canada K1G 4J5
| | - Guangheng Zhu
- 1] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [2] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - Miao Xu
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - Issaka Yougbare
- 1] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [2] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8 [3] Canadian Blood Services, Ottawa, Ontario, Canada K1G 4J5
| | - Li Ma
- 1] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [2] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8 [3] Canadian Blood Services, Ottawa, Ontario, Canada K1G 4J5
| | - Brian Vadasz
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - Naadiya Carrim
- 1] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [2] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - Renata Grozovsky
- Translational Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Min Ruan
- Department of Hematology, Anhui Medical University, Hefei 230032, China
| | - Lingyan Zhu
- Department of Hematology, Anhui Medical University, Hefei 230032, China
| | - Qingshu Zeng
- Department of Hematology, Anhui Medical University, Hefei 230032, China
| | - Lili Tao
- Department of Hematology, Anhui Medical University, Hefei 230032, China
| | - Zhi-min Zhai
- Department of Hematology, Anhui Medical University, Hefei 230032, China
| | - Jun Peng
- Department of Hematology, Qilu Hospital, Shandong University, Jinan 250012, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital, Shandong University, Jinan 250012, China
| | - Valery Leytin
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8
| | - John Freedman
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8 [4] Department of Medicine, University of Toronto, Ontario, Canada M5S 1A8
| | - Karin M Hoffmeister
- Translational Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Heyu Ni
- 1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5S 1A8 [2] Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada M5B 1W8 [3] Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science of St. Michael's Hospital, Toronto, Ontario, Canada M5B 1W8 [4] Canadian Blood Services, Ottawa, Ontario, Canada K1G 4J5 [5] Department of Medicine, University of Toronto, Ontario, Canada M5S 1A8 [6] Department of Physiology, University of Toronto, Ontario, Canada M5S 1A8
| |
Collapse
|
5
|
Tasneem S, Adam F, Minullina I, Pawlikowska M, Hui SK, Zheng S, Miller JL, Hayward CPM. Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear. J Thromb Haemost 2009; 7:685-92. [PMID: 19175495 DOI: 10.1111/j.1538-7836.2009.03284.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Multimerin 1 (MMRN1) is a large, homopolymeric adhesive protein, stored in platelets and endothelium, that when released, binds to activated platelets, endothelial cells and the extracellular matrix. OBJECTIVES The goals of our study were to determine if (i) MMRN1 supports adhesion of resting and/or activated platelets under conditions of blood flow, and (ii) if MMRN1 enhances platelet adhesion to types I and III collagen. PATIENTS/METHODS Platelet adhesion was evaluated using protein-coated microcapillaries, with or without added adhesive proteins and receptor antibodies. Platelets from healthy controls, Glanzmann thrombasthenia (GT) and severe von Willebrand factor (VWF)-deficient donors were tested. RESULTS MMRN1 supported the adhesion of activated, but not resting, washed platelets over a wide range of shear rates. At low shear (150 s(-1)), this adhesion was supported by integrins alphavbeta3 and glycoprotein (GP) Ibalpha but it did not require integrins alphaIIbbeta3 or VWF. At high shear (1500 s(-1)), adhesion to MMRN1 was supported by beta3 integrin-independent mechanisms, involving GPIbalpha and VWF, that did not require platelet activation when VWF was perfused over MMRN1 prior to platelets. MMRN1 bound to types I and III collagen, independent of VWF, however, its enhancing effects on platelet adhesion to collagen at high shear were VWF dependent. CONCLUSIONS MMRN1 supports platelet adhesion by VWF-dependent and -independent mechanisms that vary by flow rate. Additionally, MMRN1 binds to, and enhances, platelet adhesion to collagen. These findings suggest that MMRN1 could function as an adhesive ligand that promotes platelet adhesion at sites of vascular injury.
Collapse
Affiliation(s)
- S Tasneem
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Jurasz P, Stewart MW, Radomski A, Khadour F, Duszyk M, Radomski MW. Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol 2001; 134:1104-12. [PMID: 11682459 PMCID: PMC1573036 DOI: 10.1038/sj.bjp.0704343] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2001] [Revised: 08/08/2001] [Accepted: 08/15/2001] [Indexed: 02/02/2023] Open
Abstract
1. We have studied the effects of a novel agonist, solid-phase von Willebrand Factor (sVWF), on tumour cell-induced platelet aggregation (TCIPA). 2. Washed platelet suspensions were obtained from human blood and the effects of HT-1080 human fibrosarcoma cells and sVWF on platelets were studied using aggregometry, phase-contrast microscopy, and flow cytometry. 3. Incubation of platelets with sVWF (1.2 microg ml(-1)) and HT-1080 cells (5 x 10(3) ml(-1)) resulted in a two-phased reaction characterized first by the adhesion of platelets to sVWF, then by aggregation. 4. TCIPA in the presence of sVWF was inhibited by S-nitroso-glutathione (GSNO, 100 microM) and prostacyclin (PGI(2), 30 nM). 5. Platelet activation in the presence of tumour cells and sVWF resulted in the decreased surface expression of platelet glycoprotein (GP)Ib and up-regulation of GPIIb/IIIa receptors. 6. Pre-incubation of platelets with PGI(2) (30 nM) resulted in inhibition of sVWF-tumour cell-stimulated platelet surface expression of GPIIb/IIIa as measured by flow cytometry using antibodies directed against both non-activated and activated receptor. In contrast, GSNO (100 microM) did not affect sVWF-tumour cell-stimulated platelet surface expression of GPIIb/IIIa. 7. Flow cytometry performed with PAC-1 antibodies that bind only to the activated GPIIb/IIIa revealed that GSNO (100 microM) caused inhibition of activation of GPIIb/IIIa. 8. The inhibitors exerted no significant effects on TCIPA-mediated changes in GPIb. 9. Thus, sVWF potentiates the platelet-aggregatory activity of HT-1080 cells and these effects appear to be mediated via up-regulation of platelet GPIIb/IIIa. 10. Prostacyclin and NO inhibit TCIPA-sVWF-mediated platelet aggregation. The mechanisms of inhibition of this aggregation by PGI(2) differ from those of NO.
Collapse
Affiliation(s)
- Paul Jurasz
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
| | | | - Anna Radomski
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
| | - Fadi Khadour
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
| | - Marek Duszyk
- Department of Physiology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
| | - Marek W Radomski
- Department of Pharmacology, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada
| |
Collapse
|